National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cerliponase alfa (Brineura®) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

NCPE Assessment Process Ongoing
Rapid review commissioned 11/10/2017
Rapid review completed 27/11/2017
Rapid Review Outcome A full pharmacoeconomic evaluation is recommended.
HTA commissioned by the HSE 29/11/2017
Pre-submission consultation with Applicant 13/03/2018
Submission received from Applicant 02/08/2018
Preliminary review sent to Applicant 30/11/2018
NCPE assessment re-commenced 25/01/2019
Current Status NCPE Assessment ongoing